# A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Source: https://onco.cc/trials/nct04521231/  
OnCo record `nct04521231` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Blinatumomab in acute lymphoblastic leukaemia, run by Amgen, active and no longer recruiting.

## Summary

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL is a phase 1/2 interventional study registered as NCT04521231 by Amgen, with 181 participants enrolled, started 2021-01-04 and due to reach its primary completion in 2027-11-24. Interventions recorded: Blinatumomab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04521231
- Phase: 1/2
- Setting: A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL
- Sponsor: Amgen
- Enrolled: 181

## Sources

- ClinicalTrials.gov NCT04521231: https://clinicaltrials.gov/study/NCT04521231

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- drugs: [Blinatumomab](https://onco.cc/drugs/blinatumomab/)
- companies: [Amgen](https://onco.cc/companies/amgen/), [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)

---
JSON: https://onco.cc/api/v1/entities/nct04521231.json